<DOC>
	<DOCNO>NCT00379262</DOCNO>
	<brief_summary>The objective clinical study threefold : 1 . To compare benefit cancer control survival obtain add induction-concurrent chemotherapy radiation add concurrent-adjuvant chemotherapy radiation . 2 . To test whether replace fluorouracil Xeloda combine cisplatin chemotherapy plan maintain improve chemotherapy benefit reduce duration hospital stay . 3 . To see accelerated fractionation radiotherapy improve outcome patient compare conventional fractionation radiotherapy .</brief_summary>
	<brief_title>Therapeutic Gain Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>1. primary objective include 1. compare induction chemotherapy Cisplatin + 5-Fluorouracil versus adjuvant chemotherapy Cisplatin + 5-Fluorouracil ( PF-Pvs P-PF ) 2. compare induction chemotherapy Cisplatin + Capecitabine versus adjuvant chemotherapy Cisplatin + 5-Fluorouracil ( PX-P v P-PF ) 3. compare accelerate fractionation versus conventional fractionation ( AF v CF ) radiotherapy . 2. secondary objective include 1. compare induction chemotherapy Cisplatin + Capecitabine versus induction chemotherapy Cisplatin + 5-Fluorouracil ( PX-P v PX-P ) 2 . Comparing concurrent-adjuvant ( CA ) versus induction-concurrent ( IC ) chemotherapy sequence .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>histologically proven nasopharyngeal carcinoma primary treatment radical intent nonkeratinizing undifferentiated type stage IIIIVB ( AJCC/UICC 6th edition ) ECOG Performance status less equal 2 Marrow : WBC &gt; = 4 platelet &gt; =100 Renal : creatinine clearance &gt; =60 Informed consent Primary treatment palliative intent WHO type I squamous cell carcinoma adenocarcinoma Evidence distant metastasis Patient pregnant lactate Prior malignancy except adequately treat basal cell squamous cell skin cancer , insitu cervical cancer cancer patient diseasefree 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Nasopharyngeal Carcinoma</keyword>
	<keyword>Chemoradiotherapy</keyword>
	<keyword>Accelerated Fractionation</keyword>
</DOC>